source
- FDA places partial hold on Bright Minds' seizure trial over mouse toxicity concernsThe FDA issued a partial clinical hold on Bright Minds Biosciences' planned phase 2 trial of BMB-101 in patients with developmental and epileptic encephalopathies. The hold was triggered by precli…
- Teva halts phase 2 trial of emrusolmin for multiple system atrophy after futility analysisTeva Pharmaceuticals announced it is stopping a phase 2 study of its experimental small‑molecule drug emrusolmin, which was being tested in patients with the rare neurodegenerative condition multip…